R&D Productivity: Not So Bad After All?
Executive Summary
Falling Big Pharma R&D productivity is often cited as the industry's Achilles heel. Yet simply counting the number of drug launches each year versus R&D spend doesn't give a true picture of the industry's productivity, argue analysts at CSFB. Productivity is not falling, they say, but gains just aren't visible yet. In five years, large pharmaceutical companies-particularly those in Europe-may emerge from this fog with renewed strength.
You may also be interested in...
R&D Productivity at GSK? He CEDD, She CEDD
Management endorsed GlaxoSmithKline's new R&D structure-the CEDDs-as an overwhelming success during the Big Pharma's December 2003 R&D day. But the analyst and investor communities weren't uniformly impressed. And fair enough: regardless of GSK's excitement and the storm of numbers and early stage results that promise a robust series of product launches, it's too early to judge the success of the CEDD experiment. A lot can go wrong between now and 2008, when the pipeline will ripen or rot.
Rebuilding Big Pharma's Business Model
The blockbuster business model that underpinned Big Pharma's success is now irreparably broken: the costs of commercialization are too high and likely returns below the cost of capital. The industry needs a new approach, constructed from four inter-related building blocks--focused R&D; partnerships; customer solutions, not products; and a business unit, not functional, organizational model.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”